-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for…
Month: June 2021
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
– Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an…
ObsEva to Present Oral Presentation at the RCOG Virtual World Congress 2021
Title: A Randomised, Placebo-Controlled, Proof-of-Concept Trial of Ebopiprant for Spontaneous Preterm Labor (PROLONG) Abstract ID: 601 Presenter: Ben Mol, Ph.D.,…
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation– – Phase 2b/3 adaptive…
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
– Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an…